MTOR and nonpapillary renal cell carcinoma: As for DSS analysis, the result suggested a poor clinical outcome in ccRCC patients with high levels of MMP9, G0S2, F3 and low levels of TLR7, TLR8, CREB5, CYBB, SELP, MTOR, DYSF, SLC22A4, and KCNJ15 (Figure 6C and Table 3).